Log In
Print
BCIQ
Print
Print this Print this
 

ANX-514 (formerly SDP-014)

  Manage Alerts
Collapse Summary General Information
Company Mast Therapeutics Inc.
DescriptionLyophilized nanoemulsion formulation of docetaxel without polysorbate 80
Molecular Target Tubulin ; B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of ActionBcl-2 inhibitor; Microtubule stabilization
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer; Treat cancer
Regulatory Designation

Partner

Shin Poong Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today